Publication

Video

Supplements and Featured Publications
BTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

Author(s):

Lori A. Leslie, MD

In Partnership With:

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the utility of BTK inhibitors in B-cell malignancies.

BTK inhibitors target an enzyme that is necessary for B​-cell growth, says Leslie. ​Moreover, there are several approved indications ​for BTK inhibitors in chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma ​(MCL), and ​Waldenström macroglobulinemia.

Notably, ibrutinib (Imbruvica) ​and acalabrutinib (Calquence) ​are 2 BTK inhibitors that are approved for patients with B-cell malignancies. Moreover, zanubrutinib (Brukinsa) is currently approved in relapsed/refractory MCL and is the subject of ongoing investigation in other B-cell malignancies, Leslie concludes. 

Articles in this issue
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Building on Current Understandings of BTK Inhibition in CLL, MCL
Building on Current Understandings of BTK Inhibition in CLL, MCL
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University
May 6th 2024

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Michal Taszner, MD
July 17th 2024

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups